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Abstract
Senescent cells withdraw from the cell cycle and do not proliferate. The prevalence of senescent 
compared to normally functioning parenchymal cells increases with age, impairing tissue and 
organ homeostasis. A contentious principle governing this process has been the redox theory of 
aging. We linked matricellular protein thrombospondin 1 (TSP1) and its receptor CD47 to the 
activation of NADPH oxidase 1 (Nox1), but not of the other closely related Nox isoforms, and 
associated oxidative stress, and to senescence in human cells and aged tissue. In human 
endothelial cells, TSP1 promoted senescence and attenuated cell cycle progression and 
proliferation. At the molecular level, TSP1 increased Nox1-dependent generation of reactive 
oxygen species (ROS), leading to the increased abundance of the transcription factor p53. p53 
mediated a DNA damage response that led to senescence through Rb and p21cip, both of which 
inhibit cell cycle progression. Nox1 inhibition blocked the ability of TSP1 to increase p53 nuclear 
localization and p21cip abundance and its ability to promote senescence. Mice lacking TSP1 
showed decreases in ROS production, p21cip expression, p53 activity, and aging-induced 
senescence. Conversely, lung tissue from aging humans displayed increases in the abundance of 
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vascular TSP1, Nox1, p53, and p21cip. Finally, genetic ablation or pharmacological blockade of 
Nox1 in human endothelial cells attenuated TSP1-mediated ROS generation, restored cell cycle 
progression, and protected against senescence. Together, our results provide insights into the 
functional interplay between TSP1 and Nox1 in the regulation of endothelial senescence and 
suggest potential targets for controlling the aging process at the molecular level.
INTRODUCTION
Aging represents a major global health challenge because improvements in disease 
management prolong life but often at a substantial financial burden (1). Strikingly, 
worldwide life span elongation and disease comorbidities are strongly associated, a pattern 
typified in cardiopulmonary-vascular diseases (2). However, specific targeted therapies 
combating vascular decline in the aging process are absent despite viable regimens to 
manage vascular diseases (3). Therefore, new mechanistic challenges exist as a consequence 
of the aging process and an overall decline in holistic health. It is logical, therefore, that 
attacking the seminal cause of aging rather than individual disease processes will promote 
greater improvements in life span and quality of life (4).
Cellular senescence is recognized as a central hallmark of the aging process, which occurs 
when cells withdraw from the cell cycle and lose the capacity to proliferate in response to 
growth factors or mitogens (5, 6). Moreover, senescent vascular cells are observed in human 
atherosclerotic plaques and hypertensive samples (7, 8). Senescence is an irreversible form 
of cell cycle arrest initiated by various stresses including genotoxic and oxidative stress (9), 
leading to DNA damage, oncogene activation, and telomere shortening (10). Although 
senescent cells remain minimally functional and metabolically active, they cannot undergo 
mitosis, and augmented senescence is deleterious to organ function vis-à-vis interference 
with tissue self-renewal.
In addition to cell cycle arrest, senescent cells accumulate senescence markers, including 
senescence-associated β-galactosidase (SA-β-Gal), and secrete vasoactive factors (11). 
Matricellular thrombospondins were initially characterized as a highly abundant family of 
proteins in Werner syndrome fibroblasts, which have a severely curtailed replicative life span 
(12). Thrombospondin 1 (TSP1) abundance is inversely correlated with proliferation in some 
cell types (13). However, insight into TSP1-suppressed proliferation remains unknown.
As reported by Harman (14), oxidative stress has been considered a key driver of the aging 
process, and subsequent studies have inferred a link between oxidative stress and 
senescence. Of the highly conserved family of NADPH (reduced form of nicotinamide 
adenine dinucleotide phosphate) oxidase (Nox) isozymes, which produce reactive oxygen 
species (ROS), two isoforms are generally considered as promitotic and are pivotal to several 
pathologies involving hyperproliferation. Accordingly, interest in Nox inhibitor development 
has intensified and therefore represents an opportunity to interrogate, with therapeutic 
translation, the link between ROS and aging (15). Here, we present data suggesting a causal 
role of TSP1-induced increase in the abundance of Nox1 (but not the closely related Nox2, 
Nox4, or Nox5) in cellular senescence across a wide range of ages in humans, thus 
challenging the dogma of a primarily pro-proliferative and proapoptotic role for Nox1. We 
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provide mechanistic insight into senescence triggered by p53-p21cip-Rb, and not p16INK4A, 
in human cells and mouse models. We validated our discovery with genetic and 
pharmacological tools in tissues of humans of increasing age, in mice lacking TSP1 or 
Nox1, in human endothelial cells challenged with TSP1, and in endothelial cells 
overexpressing Nox1. Finally, our studies offer an exciting new therapeutic translation of a 
selective Nox1 inhibitor as a modality to target senescence-associated endothelial 
dysfunction.
RESULTS
TSP1 is increased in human aging and induces endothelial senescence
Age-related diseases are associated with increased matrix remodeling and matricellular 
protein abundance (12, 16–19). Of these matricellular proteins, TSP1 is intriguing because 
of its reported association with age-related pulmonary diseases including pulmonary 
hypertension, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis (20–
24). To explore the functional role of TSP1 in aging and disease, we examined whether 
TSP1 associated with human pulmonary aging by analyzing disease-free lung biopsies (table 
S1). We observed a strong positive relationship between TSP1 mRNA and increasing age 
(Fig. 1A), as is suggested by aging muscle data housed at the NCBI (National Center for 
Biotechnology Information) database (accession #GDS156). Next, we investigated TSP1 
localization in pulmonary arteries obtained by rapid autopsy of non–pulmonary-diseased 
subjects (table S2). Consistently, we observed notable differences in TSP1 
immunofluorescence across the vessel wall (Fig. 1B), with a significant increase in intimal 
TSP1 immunofluorescence in arteries from aged subjects compared to younger controls 
(Fig. 1C and fig. S1A).
We next explored the functional effects of TSP1 on endothelial cell physiology using 
primary human pulmonary artery endothelial cells (HPAECs). HPAECs were chosen 
because they are a well-characterized and readily available model for studying cell-mediated 
processes in pulmonary disease (25, 26). We found that TSP1 induced cell cycle arrest of 
HPAECs (Fig. 1D), characterized by increased numbers of cells in G1-G0 and decreased 
numbers of cells in S and G2-M (Fig. 1E). In line with the ability of TSP1 to block cell 
proliferation induced by serum, nitric oxide (NO), or fibroblast growth factor 2 (13, 27), 
TSP1 significantly inhibited HPAEC proliferation, as detected by trypan blue exclusion (Fig. 
1F), MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay (Fig. 1G), 
and 5-bromo-2′-deoxyuridine (BrdU) incorporation (Fig. 1H). This effect was achieved 
using a TSP1 concentration (2.2 nM) detected in the plasma of diseased patients (28, 29) and 
was not enhanced by higher concentrations (fig. S1, B and C).
Blunted proliferation and halted cell cycle progression are hallmarks of cellular senescence 
(6), a phenotypical switch associated with organismal aging and organ dysfunction (30). To 
ascertain a functional role for TSP1 in proliferative signaling in vivo and corroborate our 
primary findings in human cells, we assessed middle-aged (8- to 10-month-old) mouse lungs 
for proliferating cell nuclear antigen (PCNA) (31) in wild-type and TSP1−/− mice (Fig. 2A). 
Middle-aged mice were chosen because their tissues are terminally differentiated (32), 
mirroring the early stages of age-related complications in humans (33). Immunoblotting 
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revealed a significant increase in PCNA abundance in TSP1−/− mice compared to age-
matched wild-type controls. Accordingly, TSP1 exposure significantly decreased PCNA 
abundance in HPAECs (Fig. 2B). On the basis of these observations and the increase in 
expression of self-renewal genes in CD47-null endothelial cells (34), we investigated 
whether TSP1 drove HPAEC senescence. TSP1 exposure significantly increased the number 
of SA-β-Gal–positive HPAECs and human aortic endothelial cells (Fig. 2C), which showed 
concentration dependency (fig. S1D), and elicited an enlarged and flattened cell shape 
characteristic of senescence (Fig. 2D) (35), supporting a work in brain endothelial cells (36). 
To assess in vivo relevance of our discoveries, we performed SA-β-Gal staining, which was 
lower in TSP1−/− mouse lung tissue than in wild-type mouse lung tissue (Fig. 2E). This 
observation, coupled with similar collagen staining between the two genotypes (Fig. 2E, 
blue stain, and fig. S1E), precluded collagen-induced vascular senescence (37). Notably, 
middle-aged wild-type lungs were abundant in senescent markers, with increased p53 and 
p21cip, decreased Rb, and no change in p16INK4A, compared to younger controls (fig. S2A). 
Moreover, aging decreased PCNA abundance in wild-type animals. Because the senescent 
phenotype is not only associated with cell cycle arrest and cell function decline, we sought 
to ascertain the role of the senescence-associated secretory phenotype (SASP) components 
in TSP1-mediated senescence. SASP factors include many inflammatory cytokines, growth 
factors, and proteases, among others (38–40). Immunoblotting demonstrated that some 
SASP factors [monocyte chemoattractant protein-1 (MCP-1) and p19Arf] were lower in 
abundance in TSP1−/− lung homogenates compared to those from their wild-type 
counterparts (Fig. 2F). These observations in aging tissues and endothelial cells support 
TSP1 as an instigator of cellular senescence.
TSP1 promotes p53-dependent DNA damage response and senescence
The aged pulmonary vascular tree is subject to an imbalance between oxidants and 
antioxidants and attendant oxidative stress (41), a process associated with the free radical 
theory of aging (14). Therefore, a link between senescence, oxidative stress, and TSP1 could 
offer insight into the aging process. In HPAECs exposed to TSP1, O2•− and H2O2 
production, both of which are indicators of oxidase activity, were increased (Fig. 2, G and 
H). Next, we interrogated O2•− production in middle-aged wild-type and TSP1−/− lungs 
using two complementary assays. TSP1−/− lungs displayed significantly lower O2•− by en 
face fluorescence (Fig. 2I) and decreased NADPH-driven O2•− measured by the reduction of 
cytochrome c (Fig. 2J). These findings, together with increased ROS in middle-aged mouse 
lungs compared to young controls (fig. S2B), suggested a role for TSP1-induced Nox-
mediated ROS as a driver of endothelial senescence.
We discovered that TSP1 activated the DNA damage response (DDR) senescence pathway. 
Rb abundance was reduced, and Ser15 in p53 was phosphorylated in HPAECs exposed to 
TSP1 compared to vehicle control. p53-independent senescence signaling through p16INK4A 
(18) was excluded because p16INK4A abundance remained unchanged in response to TSP1 
(Fig. 3A) and was not increased in middle-aged wild-type mouse lungs (fig. S2A). This 
finding distinguished TSP1 from other matricellular proteins such as CCN1, which signals 
through p16INK4A (18). We observed an increase in total p53 and p21cip in middle-aged 
mice (fig. S2A). Moreover, we discovered that TSP1 exposure increased p53 abundance in 
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HPAECs in a time-dependent fashion (Fig. 3B) and increased p53 activation, as evidenced 
by its increased nuclear localization (Fig. 3C). Moreover, TSP1 exposure significantly 
increased the number of HPAECs positive for p21cip (Fig. 3D), the downstream 
transcriptional target of p53 activation that encodes a cell cycle–inhibiting factor (42). The 
increase in the number of SA-β-Gal–positive cells was blocked by p53 silencing, confirming 
a role for p53 in TSP1-induced endothelial senescence (Fig. 3E and fig. S2C). The 
abundance of p53 and p21cip was subsequently evaluated in mice. TSP1−/− lungs had 
significantly lower p21cip mRNA (Fig. 3F) and protein (Fig. 3G) abundance compared to 
age-matched controls, with the abundance of p53 remaining unchanged (Fig. 3, F and G) but 
active (phosphorylated) p53 decreasing markedly in nulls (Fig. 3G). Because TSP1−/− tissue 
exhibited lower amounts of O2•− (Fig. 2, I and J), we reasoned that changes in p21cip 
abundance resulted from a difference in p53 activation, as evidenced by decreased p53-Ser15 
phosphorylation (Fig. 3G) (43, 44). Because p53 evokes apoptotic signaling, we asked 
whether TSP1 promoted apoptosis of HPAECs (45). However, apoptosis, as measured by 
trypan blue cell counting (fig. S3A) and sub–G1-G0 FACS quantification (fig. S3B), was 
unaffected by TSP1 exposure. These observations are consistent with the role of TSP1 in 
p53-mediated DDR senescence, exclusive of apoptosis.
Aging-linked TSP1-mediated cellular stress is elicited by Nox1
To gain further insight into the mechanisms modulating matricellular-induced cellular O2•− 
and DDR-senescence pathway activation, we first sought to identify the receptor responsible 
for these effects of TSP1. TSP1 reportedly binds and activates several cell-surface receptors, 
three of which are prominent in the endothelium. A blocking antibody against the cognate 
TSP1 receptor CD47 attenuated TSP1-induced O2•− production in HPAECs (Fig. 4A). 
Moreover, 7N3, a receptor binding peptide that mimics the C-terminal binding domain of 
TSP1 (46, 47), significantly increased NADPH-dependent O2•− generation (Fig. 4B). In 
addition to CD47, the TSP1 receptors signal regulatory protein α (SIRPα) and CD36 are 
also present in endothelial cells (13, 48, 49). FACS analysis indicated that the abundance of 
CD47 was similar to that of SIRPα and greater than that of CD36 (fig. S4, A to C). 
However, antagonizing antibodies against SIRPα and CD36 did not significantly affect O2•− 
production (Fig. 4C and fig. S4D). Therefore, of the potential culprits, the TSP1-CD47 axis 
selectively regulated cellular O2•− production.
Because TSP1 exposure decreased NO concentrations (fig. S4E), as previously reported 
(50), we initially postulated that uncoupled endothelial NO synthase (eNOS) could be the 
major O2•− source. However, O2•− concentrations were not affected by the potent eNOS 
inhibitor Nω-nitro-L-arginine methyl ester (L-NAME), the mitochondrial inhibitor rotenone, 
or the xanthine oxidase inhibitor oxypurinol (Fig.4D). In contrast, diphenyleneiodonium 
(DPI), a broad-profile flavoprotein inhibitor that targets Nox isoforms, ablated TSP1-
induced O2•−. We have previously reported that acute TSP1 exposure activates the Nox1 
isoform in smooth muscle (46, 49). We thus used our selective Nox1 inhibitor, NoxA1ds 
(51), and a specific Nox2 inhibitor, Nox2ds-tat (52, 53). TSP1-induced O2•− production was 
abolished by the selective Nox1 inhibitor but not by the Nox2-specific inhibitor (Fig. 4E), 
and the findings with Nox1 were confirmed with siRNA-mediated gene silencing (fig. S4, F 
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and G). Consequently, these results indicated that Nox1 was the major source of TSP1-
induced O2•− in endothelial cells and potentially a source of aging-induced ROS.
To investigate a link between endothelial senescence and a TSP1-induced increase in Nox-
produced ROS, we examined the effects of TSP1 exposure on the abundance of various Nox 
subunits. Western blot analysis revealed that only the Nox1 catalytic subunit was 
significantly increased (Fig. 4F). The Nox2 catalytic subunit and NoxO1, the canonical 
Nox1 organizing subunit, exhibited a tendency toward increased abundance that was not 
significant, whereas the abundance of the Nox1 activating subunit NoxA1 or the alternate 
organizer p47phox was unaffected. FACS (Fig. 4G) and mRNA (Fig. 4H) analysis confirmed 
that TSP1 exposure significantly increased Nox1 abundance. Nox4 mRNA was significantly 
increased but to a markedly lower degree and without a corresponding increase in Nox4 
protein abundance. Supporting these cellular observations, Nox1 mRNA abundance was 
lower in the lungs of middle-aged TSP1−/− mice compared to wild-type mice (Fig. 4I). 
Similarly, we observed that Nox1 protein abundance was significantly lower in middle-aged 
TSP1−/− lungs compared to controls (Fig. 4J), with the abundance of Nox2 and Nox4 
remaining unaffected (fig. S4H). In aggregate, these results suggest that Nox1 is the 
dominant oxidase mediating TSP1-induced endothelial DDR senescence.
Nox1 is a target in human matrix protein–mediated endothelial senescence
We postulated that increased Nox1 abundance was sufficient to induce HPAEC senescence. 
Nox1 reportedly displays constitutive activity, generating O2•− because of interactions 
between the catalytic membrane-spanning Nox1 subunit in association with p22phox and the 
cytosolic organizing NoxO1 and activator NoxA1 subunits bound through C-terminal 
interactions with Rac1/2 (54). Consistent with our hypothesis, the number of SA-β-Gal–
positive cells was significantly increased in cells transfected with human Nox1 (Fig. 5A) 
compared to empty plasmid controls. Nox1 overexpression (Nox1OE) was confirmed by 
FACS analysis (fig. S5A) and mirrored increased O2•− production (Fig. 5B and fig. S5B). 
Furthermore, middle-aged Nox1-null (Nox1−/−) mice produced significantly less pulmonary 
NADPH-driven O2•− than wild-type mice (Fig. 5C). Moreover, decreased Nox1-derived 
O2•− was linked to a significant decrease in p21cip expression without changes in p53 
expression (Fig. 5D). These in vivo results were corroborated with Nox1OE cells, which 
showed increased p21cip abundance and decreased Rb phosphorylation (fig. S5C). To 
confirm the role of Nox1 as a potential therapeutic strategy in age-related TSP1-induced 
senescence, we investigated the ability of the selective Nox1 inhibitor NoxA1ds to attenuate 
the effects of TSP1 in vitro. In both the MTT-based assay (Fig. 5E) and trypan blue assay 
(Fig. 5F), NoxA1ds reversed the ability of TSP1 to inhibit endothelial cell proliferation. 
Moreover, NoxA1ds treatment restored normal cell cycle progression in HPAECs exposed to 
TSP1 (Fig. 5G). In contrast, Nox1OE reduced cell proliferation (fig. S5D) and cell cycle 
progression (fig. S5E). Consistent with the notion that TSP1-induced senescence was Nox1-
mediated, TSP1 promoted increased p53 nuclear localization and p21cip induction in control 
cells (Fig. 5H, top), effects that were abrogated by Nox1 inhibition (Fig. 5H, bottom). 
Moreover, NoxA1ds restored PCNA abundance in TSP1-challenged cells (fig. S5F). These 
findings support a model in which Nox1 orchestrates TSP1-induced endothelial cell 
senescence through a DDR-dependent mechanism.
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Translational relevance of our in vitro and in vivo findings was further assessed in human 
lung biopsies from disease-free subjects and mice of varying ages. We detected a strong 
correlation between the rates of generation of O2•− (Fig. 6A) and its metabolite H2O2 (Fig. 
6B) in human lung homogenate with advancing age. We also addressed whether Nox1 
abundance was increased with advancing human age because of growing evidence for a role 
for Nox1 in promoting myriad pathologies (55–59). We showed a significant correlation 
between increasing age and the abundance of Nox1 protein (Fig. 6C) and a trend toward an 
increase in mRNA (fig. S6A) in humans. No significant change in protein was observed with 
other vascular isoforms (Nox2, Nox4, or Nox5; fig. S6, B to E). An increase in Nox1 
abundance but not that of Nox2 or Nox4 was also corroborated in middle-aged mouse lungs 
compared to young controls (fig. S6F). Accordingly, human aging correlated significantly 
with the abundance of p53 and p21cip (Fig. 6D). Further supporting the potential clinical 
relevance of our findings, we discovered that Nox1 localized predominantly in the intima of 
human pulmonary arteries (Fig. 6E, top) and was significantly increased in samples from 
older subjects compared to those from younger subjects. Similarly, confocal visualization 
identified increased p21cip with human age in the intimal endothelium (Fig. 6E, bottom), 
consistent with the clinical translation potential of this pathway. Finally, we confirmed that 
Nox1 mediated the senescence phenotype in response to TSP1 because NoxA1ds attenuated 
TSP1-induced senescence in HPAECs (Fig. 6F). Together, these results highlight a role for 
Nox1 in aging-associated endothelial p53-mediated activation of the DDR pathway and in 
driving a prosenescent phenotype. Furthermore, agents targeting Nox1 hold promise for 
slowing or averting this cell fate.
DISCUSSION
Cell senescence is a major hallmark and underpinning of age and premature death. 
Undoubtedly, over the past two centuries, mankind has seen major improvements in life 
span, largely as a result of treatment of targeted organ dysfunction and disease. Now, 
however, there is reasonable concern that extant drug regimens have become so effective that 
new strategies will yield incremental or, in combination, deleterious effects. Thus, a more 
fundamental and mechanistic inquiry into the root cause of organismal decline might be 
expected to yield substantively greater gains in the length and quality of life. With an aging 
global population, a better understanding of the fundamental mechanisms underlying age-
related senescence is of paramount importance (60). We proffer that the study of the actions 
of matricellular proteins in aging could advance our knowledge of this process. Matricellular 
proteins increase with age (61), but a causal, rather than a circumstantial, relationship has 
not been investigated to date.
Associations between increasing age and cardiovascular complications are particularly 
striking (2, 62, 63). Thus, improved mechanistic insight and identification of molecular 
targets in age-related vascular disease are critical. Cellular senescence, occurring when cells 
withdraw from the cell cycle and lose the capacity to proliferate in response to growth 
factors or mitogens (6), was first described in rapidly replicating human fibroblasts. 
Senescence is an irreversible form of cell cycle arrest initiated by various stresses, including 
genotoxic and oxidative stress (9), leading to DNA damage, oncogene activation, and 
telomere shortening (10). However, endothelial cell senescence may be considered 
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protective in its ability to stave off vascularization and, in turn, blunt tumor growth (64). On 
balance, however, augmented senescence with age is deleterious to organ function vis-à-vis 
interference with tissue self-renewal. Here, we discovered that the matricellular protein 
TSP1 played a role in human endothelial senescence by increasing the abundance and 
activation of the Nox1 isozyme. In turn, Nox1-dependent ROS led to p53-p21cip-Rb DDR 
pathway activation and endothelial cell senescence (Fig. 7). This pathway was interrogated 
using (i) human clinical biopsies and pulmonary artery samples, (ii) genetically modified 
middle-aged mice lacking TSP1 or Nox1, (iii) primary human endothelial cells, and (iv) 
human Nox1-overexpressing endothelial cells. Supporting the impact of our findings, 
translational application was demonstrated using a selective Nox1 inhibitor in human cells.
Findings of increased TSP1 abundance in aged mouse cardiac tissue (65) sparked our 
interest into the role of TSP1 in the decline of cellular and organ function in the aging 
process. Here, we discovered a link between age and TSP1 abundance in human lung 
biopsies, which aligns mechanistically with TSP1-induced human endothelial cell cycle 
arrest and decreased proliferation corroborated by three independent methods (Fig. 1). These 
data were supported by a mouse model of aging in vivo, in which deletion of TSP1 resulted 
in increased PCNA abundance. Moreover, in human endothelial cells, TSP1 decreased 
PCNA abundance and enhanced senescence, as distinguished by β-Gal staining and cell 
morphology (Fig. 2). Tissues fromTSP1−/− mice showed decreased senescence compared to 
those from age-matched wild-type mice. Together, our current findings identified a role for 
TSP1 in endothelial senescence, which involves cell cycle progression inhibition, oxidative 
stress, and p53-mediated DDR signaling.
Organ homeostasis is perturbed upon the accumulation of somatic senescent cells in tissues 
(5, 6). Hence, senescence is considered an inexorable cell fate in mammals and other 
organisms (30, 66) and represents a maladaptive response leading to dysfunction and 
vascular disease. One suggested determinant of in vivo senescence at the molecular level 
corresponds to the accumulation of oxidative damage triggered by a chronic mild increase in 
ROS (9). These ROS (for example, O2•− and its more stable and cell-permeant H2O2 
product) can impair normal cellular processes by oxidizing macromolecules and damaging 
organelles (67) and have been associated with disease progression (41). Our data align with 
the free radical theory of aging in two ways. We discovered a key relationship between age, 
Nox1, and human lung ROS (Fig. 6). Second, our findings support matricellular TSP1 
inducing human endothelial cell ROS and senescence, along with an exhibited suppression 
of O2•− production in TSP1−/− mouse lungs (Fig. 2). Our findings, combined with reduced 
senescence and SASP factors in these knockout animals, underscore a functional link 
between TSP1, Nox1, and senescence.
Of the macromolecules altered by ROS, dysfunctional oxidized DNA repair commits cells to 
senescence through activation of the DDR pathway, a phenomenon that has been observed in 
various forms of cancer, neurodegenerative disorders, and infertility (68, 69). A common 
ancestral feature shared in DDR senescence is the effector p53 (67), which, after Ser15 
phosphorylation, facilitates S-phase transition blockade through transcriptional regulation of 
p21cip (44). In cultured HPAECs, we observed a time-dependent increase in p53 abundance 
and activation (as visualized by nuclear localization) and reversal of TSP1-induced 
Meijles et al. Page 8
Sci Signal. Author manuscript; available in PMC 2018 April 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
senescence by p53 knockdown (Fig. 3). We ruled out apoptosis in this response by trypan 
blue exclusion and FACS (fig. S3). These findings were corroborated in middle-aged mice 
by demonstrating that TSP1 deficiency suppressed the abundance of p21cip but not that of 
p53 (Fig. 3). In human biopsies, we observed a correlation between TSP1 induction of p53-
mediated senescence and increasing age (Fig. 6).
Senescence relies on two main molecular pathways: p16INK4A-Rb and p53-p21cip-Rb 
signaling. Both pathways converge at the level of Rb, and hypophosphorylated Rb with p53 
indicates committed senescence (42). TSP1 promoted p53-p21cip-Rb–dependent senescence 
independently of p16INK4A-Rb. These findings contrast with the effects of CCN1, another 
matricellular protein that promotes both p53- and p16INK4A-dependent fibroblast senescence 
(18), and may suggest a greater role for TSP1 in committed senescence. However, these 
disparate signaling effects could be cell- and context-dependent and perhaps hinge on the 
components in a specific milieu of other pro-proliferative and senescence factors. Moreover, 
given that p53 increases the intracellular abundance of TSP1, which stabilizes p53 tumor 
suppressor activity (20), it is tempting to speculate that a vicious cycle of TSP1-Nox1-p53 
signaling is set in motion. Further studies are warranted to explore this phenomenon.
We have previously reported that TSP1 induces cellular ROS (46, 49). In contrast, the 
endothelial cell response described here differs in its robust and sustained cumulative signal 
necessary for senescence induction. We provided evidence to show that TSP1 promoted 
specific human endothelial Nox1-derived ROS generation through CD47 but not SIRPα 
receptor engagement. These conclusions are drawn from (i) an observed increase in only 
Nox1 in HPAECs by Western blot, FACS, and mRNA analysis; (ii) effective inhibition and 
induction of ROS by blocking and stimulating CD47, respectively; and (iii) the ability of the 
Nox1-specific inhibitor NoxA1ds, but not of Nox2ds-tat (which is Nox2-specific), to 
suppress ROS (Fig. 4). The latter was corroborated using Nox1 siRNA (fig. S4). Moreover, 
TSP1 knockdown in aged mice elicited a decrease in Nox1 (but not in Nox2 or Nox4) at the 
mRNA and protein levels. Endothelial Nox1 (58, 70) exists in a constitutively active form or 
an inducible form (71). Because we discovered that human and murine aging, as well as 
TSP1 exposure, increased Nox1 abundance, we assert that the increase in ROS we observed 
is attributable to constitutive and chronic Nox1 activity. Thus, we submit that this chronic 
ROS generation, in turn, persistently drives DDR-related endothelial senescence (59).
Our findings that human Nox1 overexpression (Nox1OE) in HPAECs augmented the 
senescent phenotype are consistent with our observations of increased Nox1 abundance in 
aged human lung vasculature and after TSP1 challenge. Moreover, Nox1−/− deficiency 
lowered ROS production and p21cip abundance in middle-aged mice. In human cells, Nox1 
inhibition reversed the ability of TSP1 to suppress proliferation and cell cycle progression 
and induce p53 nuclear localization and p21cip-positive cells. Further, overexpressing Nox1 
resulted in increased ROS production, senescence, p21cip abundance, and Rb 
hypophosphorylation, consistent with a role of Nox1 in these processes (Fig. 5 and fig. S5). 
Together, these findings support the role of Nox1 in propagating endothelial ROS-induced 
senescence.
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Finally, clinical and therapeutic implications of our findings were illustrated by age-
dependent increases in two readouts of Nox-derived ROS production (O2•− and H2O2) in 
human lungs, along with robust increases in Nox1, p53, and p21cip (Fig. 6). Complementing 
these data further were cross sections of pulmonary artery illustrating a higher abundance of 
Nox1 and p21cip in the luminal endothelium. Finally, targeting Nox1 with its specific 
inhibitor NoxA1ds quelled senescence of human endothelial cells.
Members of the Nox family of isozymes, namely, Nox1, Nox2, and Nox4, have roles in 
proliferation and vessel remodeling (33, 72, 73). Thus, we did not expect Nox enzymes to 
play a role in aging-associated senescence. Finally, the specific transcriptional activators that 
increase Nox1 expression in the aging process will require exploration. The Nox1 promoter 
is reportedly responsive to various factors (74).
In summary, we found that a matricellular protein–induced, Nox1-derived ROS was 
responsible for p53-p21cip-Rb signaling and senescence, which were attenuated by Nox1 
inhibition. Our findings linking TSP1/CD47, Nox1, and p53/p21/Rb to senescence in animal 
and human cells and during aging in human tissues are unique and previously unreported 
from both a mechanistic and a clinical standpoint. Finally, the exogenous delivery of Nox1 
inhibitor(s) could offer therapeutic utility in the aging lung and other age-related 
pathologies.
MATERIALS AND METHODS
Materials and reagents
Cytochrome c, superoxide dismutase (SOD), catalase, DPI, L-NAME, rotenone, 
phenylmethylsulfonyl fluoride (PMSF), β-Gal, and other reagents were purchased from 
Sigma-Aldrich. Amplex Red and propidium iodide were purchased from Invitrogen. 
Protease and phosphatase inhibitor cocktail tablets were purchased from Roche Diagnostics 
GmbH. Human TSP1 was purchased from Athens Research and Technology. Peptide 7N3 
(RFYVVMYEGKK) was synthesized by Peptides International Inc. BrdU cell proliferation 
kit was from Cell Signaling Technology.
Human samples
The study was approved by the University of Pittsburgh Institutional Review Board, and 
written informed consent was obtained from all participating individuals. Lung and 
pulmonary artery (fifth branch) tissues from control non–pulmonary-diseased lung donors 
were provided by the PACCM (Division of Pulmonary, Allergy and Critical Care Medicine) 
Bio-Bank under protocols approved by the University of Pittsburgh Institutional Review 
Board. Tissues were harvested in optimal cutting temperature (OCT) medium, frozen, and 
sectioned (8 μm) for subsequent analysis (see below).
Animals
All animal studies were performed under a protocol approved by the Institutional Animal 
Care and Use Committee of the University of Pittsburgh. TSP1−/− and Nox1−/− mice (8 to 10 
months old) on a C57BL/6 background, and age-matched wild-type C57BL/6 control mice 
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were purchased from the Jackson Laboratory. Animals were sacrificed, and lungs were 
collected and either snap-frozen or embedded in OCT medium and frozen for further 
analysis.
HPAEC culture, TSP1 challenge, blocking antibody experiments, and NoxA1ds treatment
HPAECs (Lonza) were grown in EBM-2 (endothelial growth basal medium-2) containing 
EGM-2 (endothelial cell growth medium-2) BulletKit components (Lonza). Cells (passages 
3 to 6) were seeded the day before the experimentation and synchronized in serum-reduced 
medium (1% fetal bovine serum) for 4 hours. Synchronized endothelial cells were treated 
with vehicle or TSP1 (2.2 nM) for 24 hours (or as indicated) and subjected to either 
homogenization in ice-cold disruption buffer (Hanks’ balanced salt solution containing 1.8 
mM CaCl2, 0.8 mM MgCl2, and 0.1 mM PMSF), fixation in 2% paraformaldehyde/
phosphate-buffered saline (PBS), or trypsinized for intact cell analysis. In some studies, 
blocking antibodies to CD47 (clone B6H12, Santa Cruz Biotechnology), SIRPα (clone C20, 
Santa Cruz Biotechnology), or CD36 (clone H-300, Santa Cruz Biotechnology) were added 
to the cell culture medium (1 mg/ml) for 3 min before TSP1 challenge. In addition, specific 
inhibition of the Nox1 enzyme was achieved using the NoxA1ds (10 μM) peptide (51) or its 
scrambled-ds peptide control (10 μM). In these experiments, cells were pretreated with 
peptides for 1 hour before TSP1 (2.2 nM) challenge.
siRNA gene silencing and Nox1 plasmid transfection
HPAECs were seeded at a density to achieve a 75 to 80% confluence overnight and were 
subjected to either p53 or Nox1 siRNA transfection (Santa Cruz Biotechnology) using the 
Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer’s 
protocol, as documented previously (51). To control for possible nonspecific effects of 
siRNA, control siRNA was used. Gene silencing was confirmed using immunoblotting, and 
the knockdown was expressed as a fold of siRNA controls. Nox1OE was achieved by 
transfecting cells with human Nox1 or an empty plasmid vector control, as published 
previously (75).
Cell proliferation assay
The in vitro proliferative capacity of HPAECs was analyzed using three independent assays. 
MTT proliferation assay was performed as described previously. Briefly, HPAECs were 
suspended in EGM-2–containing EBM-2 and plated on flat-bottomed 96-well plates at a 
density of 1 × 105 cells per well in triplicate. After overnight seeding (16 hours), cells were 
challenged with TSP1 (2.2 nM), and proliferation was assessed using MTT (Sigma-Aldrich) 
assay. Absorbance at 570 nm was read using a plate reader (BioTek Synergy 4 Hybrid Multi-
Mode Microplate Reader), and the proliferation index was calculated relative to the 
absorbance value of the vehicle-treated controls. Trypan blue exclusion assay was performed 
as documented previously (76). Briefly, TSP1 (2.2 nM) was added to cultures of HPAECs 
for indicated periods after an overnight seeding and a 4-hour synchronization. Subsequently, 
cells were trypsinized, 10 μl of trypan blue (4% solution) was added to an equal volume of 
cell suspension, and cell numbers were counted using a hemocytometer. Cell numbers were 
normalized and expressed as a fold change over time from the start of the experiment (time, 
0 hour). BrdU assay was performed as per the manufacturer’s instructions.
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Cell cycle analysis
HPAECs were treated with TSP1 (2.2 nM; 24 hours), trypsinized, and analyzed for cell cycle 
phase analysis, as described previously (76). Briefly, after fixation in ice-cold 70% ethanol/
PBS, cells were treated with ribonuclease A (0.2 mg/ml), and DNA content was stained with 
propidium iodide (50 μg/ml) at room temperature for 45 min. The number of cells in G0-G1, 
S, and G2-M phases and sub–G0-G1 apoptotic cells (77) was counted using a BD 
LSRFortessa flow cytometer and analyzed using the FlowJo software (version 10). A 
minimum of 10,000 events was recorded for each sample and are expressed as a percentage 
for each cell cycle phase.
Immunofluorescence
Immunofluorescence microscopy was performed as described previously using endothelial 
cells cultured on 1% gelatin–coated chamber slides (78, 79). Primary antibodies were used 
at a 1:200 dilution in PBS with 0.1% bovine serum albumin (BSA) for 60 min at room 
temperature after a 15-min permeabilization of the cells in 0.25% Triton X-100 and 0.5% 
BSA/PBS. Species-specific fluorochrome-conjugated secondary antibodies (1:500) were 
applied to detect specific antigen localization, using fluorescein isothiocyanate (FITC) 
(green), Cy3 (red), and Cy5 (gray) as fluorochromes. DAPI (blue) was used to visualize the 
nuclei. Normal rabbit or goat immunoglobulin G (5 μg/ml) was used in the place of primary 
antibody as a negative control. Images were acquired on an Olympus FluoView-II inverted 
confocal microscope system and stored digitally for analysis. For immunofluorescence 
labeling of lung and pulmonary artery sections, 5-μm sections of OCT-embedded tissue were 
first washed with PBS and blocked in 10% BSA/PBS solution for 30 min at room 
temperature after permeabilization. To detect specific antigens, the staining procedure was 
performed as described above.
SA-β-Gal staining
HPAEC and lung senescence analysis was performed as detailed previously (35, 80). Briefly, 
samples were fixed in a 2% paraformaldehyde/PBS (pH 7.4) solution for 15 min at room 
temperature, washed in PBS twice, and then incubated with the freshly prepared SA-β-Gal 
staining solution [citric acid/sodium phosphate buffer (pH 6.0) containing X-Gal (1 mg/ml), 
5 mM Fe(CN)63−, 5 mM Fe(CN)64−, 150 mM NaCl, and 2 mM MgCl2] for 24 hours in a 
humidified chamber placed in a non-CO2 incubator to maintain a buffered solution at pH 
6.0. The following day, samples were washed in PBS twice, and images were captured at 
random using a light microscope (Leica Imaging Systems Ltd.). At least six images 
representing each condition were captured from each well and were blindly assessed for SA-
β-Gal (blue)–positive cells.
Immunoblotting
Total cell and lung homogenates were generated as described previously (78). Soluble 
protein concentrations of the homogenates were determined using a plate-based Bradford 
assay kit (Thermo Fisher Scientific). Immunoblotting was conducted by loading 35 μg of 
protein per lane, as described previously (46). The images were captured digitally using a 
LI-COR biotechnology system, and the optical density of the protein bands was normalized 
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to the loading control bands (quantified using ImageJ). Results were normalized to β-actin 
loading controls in each gel and expressed as a fold change from vehicle treatment.
FACS analysis of receptor and protein expression
CD47, SIRPα, and CD36 were assessed by FACS, as published previously (81). Briefly, 
intact HPAECs after trypsinization were incubated with primary antibodies, washed, and 
incubated with fluorescently labeled secondary antibodies with either FITC or Cy5. In some 
cases, notably when detecting Nox1, p21cip, or phospho-Rb by FACS, cellular 
permeabilization in 0.25% Triton X-100/PBS and blocking in 1% BSA/PBS for 30 min on 
ice were required. After antibody labeling, cells were counted using a BD LSRFortessa flow 
cytometer and analyzed using the FlowJo software (version 10). A minimum of 10,000 
events were recorded for each sample.
ROS measurement
ROS production in endothelial cells was measured using four independent complementary 
assays. O2•− production by total cellular homogenates was measured by cytochrome c 
reduction, as described previously (46). O2•− production was initiated by the addition of 180 
μM NADPH and was calculated from the initial linear rate of SOD (150 U/ml)–inhibitable 
cytochrome c reduction quantified at 550 nm and using an extinction coefficient of 21.1 
mM−1 cm−1 (BioTek Synergy 4 Hybrid Multi-Mode Microplate Reader). Potential 
enzymatic sources of O2•− production were also investigated by using the following 
inhibitors: DPI (20 μM; flavoproteins), L-NAME (100 μM; NO synthases), rotenone (50 
μM; mitochondrial complex I), or oxypurinol (100 μM; xanthine oxidase). Endothelial cell 
homogenate H2O2 production was measured using the Amplex Red (Invitrogen Inc.) assay, 
as described previously. Briefly, protein (50 μg/ml) was added to the wells on a 96-well plate 
containing the assay mixture [25 mM Hepes (pH 7.4) containing 0.12 M NaCl, 3 mM KCl, 1 
mM MgCl2, 0.1 mM Amplex Red, and horseradish peroxidase (0.32 U/ml)]. The reaction 
was initiated by the addition of 36 μM NADPH, as published previously (46). Fluorescence 
was detected using the BioTek Synergy 4 Hybrid Multi-Mode Microplate Reader with a 
530/25 excitation and a 590/35 emission filter. The reaction was monitored for 30 min at 
25°C; the change in emission intensity was linear during this interval. To confirm the H2O2 
signal, catalase (300 U/ml) was added in parallel wells, and the catalase-inhibitable rate of 
H2O2 production was quantified from an H2O2 standard curve. Lung ROS generation was 
investigated using the cytochrome c assay in total lung homogenates (see above), as well as 
using in situ DHE analysis of OCT-embedded mouse lung sections. Briefly, 5-μm-thick lung 
sections were incubated at room temperature with DHE (10 μM) for 30 min. Sections were 
examined by fluorescence microscopy (Leica Imaging Systems Ltd.), and fluorescence 
(490/580-nm excitation/emission wavelengths) intensity from 20 fields of lung sections was 
evaluated using the ImageJ software. In parallel sections, Tiron (cell-permeant O2•− 
scavenger; 10 mM) was added to determine the proportion of DHE fluorescence that was 
O2•−-dependent. Results obtained from fluorescence imaging are expressed as Tiron-
inhibitable fluorescence intensity. Finally, to corroborate the results, ROS production was 
assessed by lucigenin-enhanced luminescence assay, as published previously (81).
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Quantitative reverse transcription polymerase chain reaction
Total RNA was extracted from lung tissues using the RNeasy Plus kit (Qiagen) as per the 
manufacturer’s protocol. Total RNA was reverse-transcribed to complementary DNA by 
using SuperScript III (Invitrogen Inc.) following the manufacturer’s protocol. For qRT-PCR, 
commercially available primers for TSP1, Nox1, p53, and p21cip (Invitrogen Inc.) were 
used. All results were normalized to the housekeeping gene 18S, and relative quantification 
was obtained using the ΔCt (threshold cycle) method; relative expression was calculated as 
2−ΔΔCt.
Statistics
Data are means ± SEM of the results from at least three independent cell cultures, at least 
four to six animals per group, or six to eight human samples per group, as detailed in the 
figure legends. Comparisons were made by unpaired Student’s t test, Mann-Whitney test, 
linear regression, repeated-measures analysis, or one-way ANOVA. P < 0.05 was considered 
statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. TSP1 is increased in aging human lung vasculature and induces endothelial cell cycle 
arrest in vitro
Data for human tissue are shown in green; data for cell experiments are shown in red; data in 
gray are the corresponding controls. (A) Correlation of TSP1 expression as quantified by 
quantitative reverse transcription polymerase chain reaction (qRT-PCR) with age in human 
lung homogenates (n = 7 subjects; r2=0.69, P = 0.02). Data points are means of three 
replicates of the same sample. (B) Representative images of TSP1 protein abundance in the 
intimal and medial layer of human pulmonary arteries of a 73-year-old subject (right; arrows 
indicate intima) compared to an artery from a 36-year-old subject (left) as determined by 
immunofluorescence (IF). Scale bar, 100 μm. L, vascular lumen. (C) Quantitation of 
immunofluorescence images from six subjects (n = 4 samples each, 10 to 20 images per 
sample) is plotted as a linear regression; equation, r2, and P values are as indicated. MFI, 
mean fluorescence intensity. (D) Cell cycle profile analysis of vehicle (left) and TSP1-
challenged (right) HPAECs measured by propidium iodide (PI) labeling and fluorescence-
activated cell sorting (FACS). FL-2, fluorescence channel 2. (E) Quantitative analysis of cell 
cycle phase distribution of HPAECs. Data are the means ± SEM of 20,000 events (n = 4 
biological replicates per treatment group) expressed as percentage. *P < 0.05 for TSP1 
challenge compared to vehicle control by Mann-Whitney test of each phase. (F and G) 
HPAEC proliferation in the presence or absence of TSP1, as measured by trypan blue 
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exclusion assay (F) and MTT assay (G). Data are means ± SEM (n = 3 biological replicates 
per treatment). P < 0.001 for TSP1 compared to vehicle control by repeated-measures 
analyses. (H) BrdU incorporation in HPAECs in the presence or absence of TSP1 at 24 
hours. Data are means ± SEM (n = 3 biological replicates per treatment). *P < 0.05 for TSP1 
challenge compared to vehicle control by Student’s t test.
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Fig. 2. TSP1 promotes cell and tissue senescence in vitro and oxidative stress in wild-type middle-
aged mice
Data for TSP1−/− samples are plotted in purple; data for cell experiments are in red; data in 
gray represent the corresponding controls. (A and B) Abundance of the S phase–associated 
proliferation marker PCNA in middle-aged TSP1−/− mice (purple bar) compared to age-
matched wild-type controls (gray bar) as analyzed by Western blotting (A) and in HPAECs 
exposed to TSP1 as analyzed by immunofluorescence (B). Data are means ± SEM [n = 6 
animals per group (A); n = 3 cell populations per treatment, 10 to 20 images per 
immunodetection (scale bar, 20 μm)] (B); *P < 0.05 compared to wild-type or vehicle 
control by Student’s t test. (C to F) Endothelial cell senescence as detected by SA-β-Gal 
labeling [C; HPAECs and human aortic endothelial cells (HuAoECs)] and increases in cell 
size (D; HPAECs). SA-β-Gal (E, left) and trichrome staining (E, right) were used on en face 
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tissue to visualize senescence, gross lung vessel morphology, and collagen deposition (blue) 
in middle-aged wild-type and TSP1−/− lungs. The abundance of SASP factors [MCP-1, 
p19Arf, and interleukin-6 (IL-6)] was assessed by Western blotting in middle-aged TSP1−/− 
and age-matched wild-type controls (F; purple compared to gray bars). Data are means ± 
SEM (n = 3 independent experiments or n = 3 animals; 12 images per group). Scale bar, 100 
μm. *P < 0.05 for TSP1 challenge compared to vehicle control or null compared to age-
matched wild-type mice by Student’s t test. (G and H) NADPH-driven O2•− (G; cytochrome 
c assay) and H2O2 (H; Amplex Red assay) production in HPAEC lysates. Data are means ± 
SEM (n = 4 biological replicates per treatment). *P < 0.05 compared to vehicle controls by 
Student’s t test. (I and J) En face cell-permeant O2•− scavenger (Tiron)–inhibitable 
dihydroethidium (DHE)–ROS, as measured by fluorescence microscopy (I), and NADPH-
driven homogenate O2•− production, as measured by cytochrome c reduction (J). Data are 
means ± SEM (n = 3 to 6 mice per group). Scale bar, 50 μm. *P < 0.05 compared to wild-
type controls by Student’s t test. a.u., arbitrary units.
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Fig. 3. TSP1 induces DDR-p53-p21cip
–mediated senescence.
Data for TSP1−/− samples are depicted in purple; data for cell experiments are in red; data in 
gray are the corresponding controls. (A) Abundance of Rb, total and phospho-Ser15 p53, and 
p16INK4A after 24 hours of TSP1 challenge in HPAECs, as measured by Western blot. Data 
are means ± SEM (n = 3 biological replicates per treatment); *P < 0.05 compared to vehicle 
by Student’s t test. (B) Time-dependent changes in p53 abundance in HPAECs stimulated 
with TSP1, as measured by Western blot. Graphical data are means ± SEM (n = 3 biological 
replicates per treatment), by repeated-measures analysis. (C and D) Activation of the p53 
pathway, as assessed by nuclear localization of p53 (C), and p21cip abundance (D), as 
measured by immunofluorescence, compared to vehicle controls. Data are means ± SEM (n 
= 3 biological replicates per treatment; 12 to 20 images per sample). Scale bar, 40 μm. *P < 
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0.05 for TSP1 challenge compared to vehicle control by Student’s t test. DAPI, 4′,6-
diamidino-2-phenylindole. (E) Effect of p53 knockdown by small interfering RNA (siRNA) 
on TSP1-induced senescence in HPAECs. Graphical data are means ± SEM (n = 3 biological 
replicates per treatment). Scale bar, 40 μm. *P < 0.05 for TSP1 challenge compared to 
vehicle control; #P < 0.05 for p53 siRNA-TSP1 compared to scrambled siRNA (SCR)–TSP1 
by one-way analysis of variance (ANOVA). (F) mRNA expression of p53 and p21cip in 
middle-aged TSP1−/− animals. Data are means ± SEM (n = 3 individual animals for each 
group). *P < 0.05 compared to wild-type by Student’s t test. (G) Abundance of p21cip and 
total and phospho-p53 in middle-aged TSP1−/− lungs compared to wild-type, age-matched 
controls. Graphical data are means ± SEM (n = 6 animals per group). *P < 0.05 for 
TSP1−/−compared to wild-type by Student’s t test.
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Fig. 4. TSP1 induces Nox1-dependent O2•− production in HPAECs through its receptor CD47
Data for TSP1−/− samples are shown in purple; data for cell experiments are shown in red; 
data in gray are the corresponding controls. (A and B) NADPH-driven O2•− production, as 
measured by cytochrome c reduction assay in HPAECs exposed to TSP1 in the presence or 
absence of a specific CD47 blocking antibody (Ab) (A) or the CD47-activating peptide 7N3 
(B). Data are means ± SEM (n = 3 biological replicates per treatment). *P < 0.05 for TSP1 
challenge compared to vehicle control (veh) by one-way ANOVA and t test, respectively. (C) 
TSP1-induced O2•− production in HPAECs exposed to a specific SIRPα blocking antibody. 
Data are means ± SEM (n = 3 biological replicates per treatment). *P < 0.05 for TSP1 
challenge compared to vehicle control by one-way ANOVA. (D) TSP1-induced O2•− 
production in HPAECs exposed to inhibitors of eNOS (L-NAME), mitochondrial complex I 
[rotenone (Rot)], or xanthine oxidase [oxypurinol (Oxy)]. Data are means ± SEM (n = 3 
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biological replicates per treatment). *P < 0.05 for TSP1 challenge compared to inhibitor 
vehicle control; #P < 0.05 for inhibitor compared to TSP1-vehicle by Student’s t test. (E) 
TSP1-induced O2•− production in HPAECs pretreated with the Nox1- and Nox2- specific 
inhibitory peptides, NoxA1ds (left) or Nox2ds-tat (right) or their respective scrambled 
controls (SCRAMB). Data are means ± SEM (n = 3 biological replicates per treatment). *P 
< 0.05 for TSP1 challenge compared to vehicle by one-way ANOVA. (F to H) Abundance in 
Nox family members in TSP1-challenged HPAECs, as assessed by Western blotting (F) and 
FACS (G). Graphical data are means ± SEM (n = 3 biological replicates per treatment). *P < 
0.05 for TSP1 challenge compared to vehicle control by Student’s t test. For qRT-PCR 
analysis (H), *P < 0.05 indicates significance for TSP1 challenge compared to vehicle 
control by Mann-Whitney test. (I and J) Nox1 abundance in lungs of TSP1−/− mice and 
wild-type age-matched controls at the mRNA level as demonstrated by RT-PCR (I) and at 
the protein level as demonstrated by immunoblotting (J). Graphical data are means ± SEM 
(n = 3 to 6 animals per group). *P < 0.05 for TSP1−/− compared to wild-type control by 
Student’s t test.
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Fig. 5. Nox1 as a potential therapeutic target to inhibit matricellular-mediated endothelial 
senescence
Data for Nox1OE are shown in blue; data for Nox1−/− samples are shown in orange; data for 
cell experiments are shown in red; data in gray are the corresponding controls. (A and B) 
Effect of human Nox1OE on SA-β-Gal staining and O2•− production. Graphical data are 
means ± SEM (n = 3 biological replicates per treatment). Scale bar, 40 μm. *P < 0.05 for 
Nox1 plasmid compared to empty plasmid control by Student’s t test. (C) NADPH-driven 
O2•− production, as measured by cytochrome c reduction assay in middle-aged wild-type 
and Nox1−/− mouse lungs. Left: Representative cytochrome c kinetic curve. Right: 
Quantification of O2•− production. Bar graphs are means ± SEM (n = 6 mice per group). *P 
< 0.05 compared to wild-type by Student’s t test. (D) mRNA expression of p53 and p21cip in 
wild-type and Nox1−/− mouse lungs. Data are the means ± SEM (n = 3 mice per group); *P 
Meijles et al. Page 28
Sci Signal. Author manuscript; available in PMC 2018 April 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
< 0.05 compared to wild type by Student’s t test. (E to G) Effect of Nox1 inhibition (using 
NoxA1ds) on TSP1-induced cell cycle arrest in HPAECs, as measured by MTT assay (E), 
trypan blue exclusion assay (F), and cell cycle profile analysis (G). Graphical data are means 
± SEM (n = 3 to 4 biological replicates per treatment). *P < 0.05 for TSP1 challenge 
compared to scrambled vehicle control (SCRAMB) by one-way ANOVA. (H) Activation of 
p53 (red), as assessed by nuclear localization (DAPI-labeled, blue) and p21cip 
immunofluorescence (green) in HPAECs challenged with TSP1 in the presence or absence 
of the Nox1 inhibitor NoxA1ds. Graphical data are means ± SEM (n = 3 biological 
replicates per treatment, 12 to 20 images per group). Scale bar, 50 μm. *P < 0.05 for TSP1 
challenge compared to scrambled vehicle control by one-way ANOVA.
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Fig. 6. Potential clinical relevance of Nox1-mediated endothelial senescence in human pulmonary 
vascular tissue
Data points for human tissue are shown in green; data for cell experiments are shown in red; 
data in gray are the corresponding controls. Data for (A) to (E) are plotted as linear 
regression (n = 8 samples); equation, r2, and P values are indicated in the corresponding 
graph. (A and B) Correlation between NADPH-driven O2•− production, as measured by 
cytochrome c reduction (A), or H2O2 production, as measured by Amplex Red fluorescence 
(B), and age in human lung homogenates. (C and D) Abundance of Nox1 (C) and p53 and 
p21cip (D), as measured by Western blot of total homogenates of aging human lung. (E) 
Intimal immunofluorescence for Nox1 (top, green) and p21cip (bottom, red) in aged human 
lung sections. Scale bar, 50 μm. Graphs show linear regression analyses. (F) HPAEC 
senescence induced by TSP1 in the presence or absence of NoxA1ds, as measured by SA-β-
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Gal staining. Graphical data are means ± SEM (n = 3 biological replicates per treatment). 
Scale bar, 40 μm. *P < 0.05 for TSP1 challenge compared to scrambled vehicle control by 
Student’s t test.
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Fig. 7. A signaling model for TSP1-induced senescence
Upon binding to CD47, TSP1 activates the Nox1 complex, which generates robust and 
sustained accumulation of ROS. In turn, this triggers committed senescence through a 
pathway involving p53-p21cip–induced DNA damage response and decreased Rb 
phosphorylation. This pathway can be disrupted using the selective Nox1 inhibitor 
NoxA1ds.
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